BIOTECH MARKET RESEARCH $VERV | Ep. 628

Verve Therapeutics

Verve Therapeutics ($VERV) is approaching a critical juncture with the anticipated Phase 1b data readout for VERV-102, its next-generation in vivo base editing therapy targeting the PCSK9 gene for heterozygous familial hypercholesterolemia (HeFH), expected in Q2 2025. Investors are sharply focused on this milestone, with hopes pinned on a compelling LDL-C reduction and a clean safety profile following the earlier discontinuation of VERV-101. The results could validate Verve’s base editing platform as a one-time, durable therapeutic option for cardiovascular disease - or prompt reassessment if safety or efficacy signals fall short of expectations. Market sentiment reflects cautious optimism, with elevated volatility (+/- 145%) anticipated.

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.

🚨 ALERT: VERVE-102 Ph 1b data - in vivo base editing therapy targeting PCSK9 in heterozygous familial hypercholesterolemia (HeFH)

📅 DATE: Q2 2025

📈📉 IMPLIED VOLATILITY: +/- 145%

BACKGROUND: